產(chǎn)品名稱 | RG2 [D74] |
---|---|
商品貨號 | B165592 |
Organism | Rattus norvegicus, rat |
Tissue | brain |
Cell Type | Glioblastoma |
Product Format | frozen |
Morphology | glial |
Culture Properties | adherent |
Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease | differentiated malignant glioma |
Age | fetus, 20 days gestation |
Applications | This cell line may be used for both in vitro and in vivo studies of a rat brain tumor. It grows well in cell culture and provides a simple, reproducible glioma model when inoculated into the brains of syngeneic rats.The RG2 and F98 (ATCC CRL-2397) gliomas can be used as rat brain tumor models in experimental neuro-oncology. |
Derivation | RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor. This tumor was produced by Drs. A. Koestner and W. Wechsler at The Ohio State University in 1971. |
Tumorigenic | Yes |
Effects | Yes, in CD Fischer rats |
Comments | This cell line has been designated RG2 or RG-2 (rat glioma 2) and it is the same as that called D74-RG2 or D74.
The transplantable tumor displays an infiltrative pattern of growth within the brain. The RG2 cells are non-immunogenic in syngeneic Fischer rats despite intensive immunization. RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor. |
Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subculture Ratio: 1:4 to 1:8 Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
|
Cryopreservation | Culture medium, 95%; DMSO, 5% |
Culture Conditions | Temperature: 37°C |
Name of Depositor | RF Barth |
Deposited As | rat |
Passage History | RG2 was submitted to the American Type Culture Collection in March, 1999 at passage 3 from a culture established from a tumor. |
Year of Origin | 1999 |
References | Ko L, et al. Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol. 51: 23-31, 1980. PubMed: 7435138 Tzeng JJ, et al. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Cancer Res. 50: 4338-4343, 1990. PubMed: 2364388 Tzeng JJ, et al. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res. 51: 2373-2378, 1991. PubMed: 2015600 Kobayashi N, et al. An improved rat brain-tumor model. J. Neurosurg. 53: 808-815, 1980. PubMed: 7003068 Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neuro-Oncol. 36: 91-102, 1998. PubMed: 9525831 Swenberg JA, et al. The induction of tumors of the nervous system with intravenous methylnitrosourea. Lab. Invest. 26: 74-85, 1972. PubMed: 4333080 Swenberg JA, et al. Quantitative aspects of transplacental tumor induction with ethylnitrosourea in rats. Cancer Res. 32: 2656-2660, 1972. PubMed: 4345400 Aas AT, et al. The RG2 rat glioma model. J. Neuro-Oncol. 23: 175-183, 1995. PubMed: 7673979 Groothuis DR, et al. Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol. 41: 164-185, 1982. PubMed: 7062086 Groothuis DR, et al. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res. 43: 3368-3373, 1983. PubMed: 6850641 Rapoport SI. Osmotic opening of the blood-brain barrier. Ann. Neurol. 24: 677-684, 1988. PubMed: 3059990 Ernestus RI, et al. Polyamine metabolism in experimental brain tumors of rat. J. Neurochem. 60: 417-422, 1993. PubMed: 8419528 Ceberg CP, et al. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83: 86-92, 1995. PubMed: 7782856 Ceberg CP, et al. Enhanced boron uptake in RG 2 rat gliomas by electropermeabilization in vivo--a new possibility in boron neutron capture therapy. Anticancer Drugs 5: 463-466, 1994. PubMed: 7949252 Molnar P, et al. The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. J. Neuro-Oncol. 25: 19-28, 1995. PubMed: 8523086 Devineni D, et al. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J. Neuro-Oncol. 24: 143-152, 1995. PubMed: 7562001 Devineni D, et al. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol. 38: 499-507, 1996. PubMed: 8823490 Gallo JM, et al. Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J. Pharmacokinet. Biopharm. 21: 575-592, 1993. PubMed: 8145132 Tjuvajev J, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910, 1995. PubMed: 7728757 |
梅經(jīng)理 | 17280875617 | 1438578920 |
胡經(jīng)理 | 13345964880 | 2438244627 |
周經(jīng)理 | 17757487661 | 1296385441 |
于經(jīng)理 | 18067160830 | 2088210172 |
沈經(jīng)理 | 19548299266 | 2662369050 |
李經(jīng)理 | 13626845108 | 972239479 |